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THE FUTURE OF TRIMETHOPRIM  
AW McKinlay, BSc (Hons)
from a dissertation read before the Society on 11th February, 1981
Co-trimoxazole became available for medical use 
towards the end of 1968 and represented a 
successful marriage of the old and the new, being a 
combination of a sulphonamide and a new drug 
called trimethoprim. Today it is one of the most 
widely prescribed drugs in the United Kingdom, 
and is used extensively in urinary and respiratory 
tract infections. More recently, however, trime­
thoprim has been released for use on its own, 
and this has raised considerable controversy as to 
which is the drug of choice.
Three original claims for co-trimoxazole 
Simple laboratory tests suggest that a combination 
of trimethoprim and a sulphonamide will inhibit 
bacterial growth at concentrations lower than 
either drug on its own. More formal assays which 
compare the drugs over a range of concentrations 
confirm that the antibacterial effect of the com­
bination greatly exceeds a purely additive 
response. The drugs' interaction is said to be 
synergistic, although no single definition of the 
term synergy has ever been universally accepted.
(1) The first claim made for co-trimoxazole was 
that this synergistic effect would prove 
benefician in the clinical situation1 .
Two major categories of antibacterial drug have 
been described. Bacterio-static drugs merely 
prevent the multiplication of a bacterial culture, 
but the organisms remain viable and will grow 
again if transferred to a fresh medium. Bactercidal 
drugs actually kill the bacteria, and the number of 
viable organisims in the culture declines.
(2) The second claim put forward for co-trimo­
xazole was that although trimethoprim and 
sulphamethoxazole are bacteriostatic on their 
own, their combination is bactericidal.
(3) Finally, it was believed that a combination of 
trimethoprim and sulphamethoxazole would
prevent the emergence of trimethoprim- 
resistant bacteria.
Fundamental to this last claim was the work 
of Darrell, Garrod and Waterworth (1968)2 
which is still widely quoted. Large inocula of 
bacteria were exposed to increasing concen­
trations of trimethoprim, and resistant strains 
were shown to emerge. Resistance could not 
be induced so readily when organisms were 
exposed to a combination of trimethoprim 
and sulphamethoxazole.
Bacterial folate metabolism
Biochemical pathways involving the transfer of 
single carbon units utilise a co-factor to which the 
carbon moiety is temporarily attached. In the 
majority of cases the co-factor is tetrahydrofolic 
acid (THF). Important cellular processes that 
require TH F  include the synthesis of a number of 
amino-acids and the formation of purines which 
are amongst the basic building blocks of D N A  
and RNA. Of particular interest is the synthesis 
of thymidine from deoxyribose uridine mono­
phosphate (dUMP). In this complex reaction 
T H F  not only acts as a methyl donor but also as 
a reducing agent, being oxidised to dihydrofolate 
(DHF) in the process. The cell reconverts D H F  to 
TH F  via the enzyme dihydrofolate reductase 
(DH FR) which is crucial to the maintenance of the 
cellular pool of THF. Many of the reactions 
involving TH F are broadly similar in both 
mammalian cells and in bacteria, but they differ 
greatly with respect to their source of new folate. 
Mammals absorb preformed, exogenous folate 
from dietary sources whilst most bacteria must 
synthesise it de novo from dihydropteridine and 
para-aminobenzoic acid (PABA) (Fig. 1). Often 
bacteria can absorb exogenous P A B A  but few can 
absorb folate itself.
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■ blocked by Sulphonamides 
•  blocked by Trimethoprim
Fig. 1: The synthesis of folic acid and some 
important reactions using TH F.
The metabolic actions of sulphonamides and 
trimethoprim
Woods (1941 )3 showed that the antibacterial 
properties of sulphonamides could be antagonised 
by PABA, and it is now accepted that 
sulphonamides act as PABA analogues and 
competitively inhibit the dihydropteroate synthe­
tase (DHPS) (Fig. 1). Since mammalian cells do 
not possess this enzyme only bacteria become 
folate depleted. Moreover, since most bacteria 
cannot take up folate they are unable to bypass 
the blockade. After the Second World War 
research started on antimetabolites of folic acid 
itself resulting in a number of small molecular 
inhibitors, including trimethoprim, which exploit 
subtle differences between the DHFRs found in 
different species.
Sulphonamides and trimethoprim, therefore, 
sequentially blockade the synthesis of TH F 
by the baterial cell, and this is the conventional 
explanation for their synergistic interaction.
This argument has come under increasing 
attack recently: firstly it assumes that the folate 
pathway is a linear one, when in fact it is not.
The production of thymidine at the expense of 
TH F  and its subsequent reconversion to DHF 
introduces a cyclical series of reactions. Trime­
thoprim inhibits the crucial step and so halts the 
cycle. On purely theoretical grounds, therefore, 
it would seem that trimethoprim is probably 
the more important member of the partnership. 
Opponents of sequential blockade argue that the 
degree of inhibition is entirely dependent on the 
more effective of the two inhibitors, which is 
trimethoprim. An analogy can be drawn to a 
water-pipe on which there are a number of taps. 
The flow rate in the pipe is dictated by which­
ever tap is shut off the most. Other taps on the 
pipe make no difference to the overall flow rate. 
It has also been shown that some bacteria entirely 
resistant to sulphonamide show a classic syner­
gistic effect when this is combined with trime­
thoprim. The DHPS in such strains is known to 
be insensitive to sulphonamide and it is extremely 
difficult to explain the syngeristic effect using a 
sequential blockade model.
Poe (1976)4 has produced evidence which 
suggests that sulphonamides may bind not only 
to the DHPS but also to the bacterial D H FR. It 
is suggested that binding the sulphonamide some­
how improves the activity of trimethoprim. In 
support of this are reports that sulphonamides will 
inhibit haematopoiesis in mouse bone marrow, 
which does not contain a DHPS. The effect is 
reversed by folate and it appears that the 
sulphonamide is inhibiting the D H FR.
Bacterial resistance to sulphonamides and 
trimethoprim
Chromosomal resistance to both trimethoprim and 
sulphonamides is known to occur. The DHPS 
or DHFR may gradually mutate to a form less 
sensitive to inhibition by the drugs. Alternatively, 
the cell may produce vast quantities of enzyme 
and in this way maintains a pool of active enzyme 
molecules. Some sulphonamide-resistant staphy­
lococci overproduce PABA and so displace the 
sulphonamide from the DHPS. These 
chromosomal mechanisms rarely produce high 
level resistance. I suspect that these were the 
mechanisms that the experiments of Darrell, 
Garrod and Waterworth (1968)2 selected (see 
page 1.).
Two chromosomal mechanisms confer total
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resistance to the cell. The first is an impermea­
bility mechanism and is usually found in species 
that are intrinsically resistant. Secondly, some 
bacterial strains have dispensed with the enzyme 
thymidine synthetase, and so avoid degrading their 
pools of THF. Growth is maintained by the 
absorption of exogenous thymidine. Despite their 
somewhat perilous life-style, thymidine-dependent 
mutants can be pathogenic in man and are some­
times isolated from urinary tract infections.
A second type of bacterial resistance is carried 
on "plasmids" — small circular pieces of DNA, 
distinct from the chromosome, that can replicate 
and maintain themselves stably over many 
generations. It has been known for many years 
that some plasmids can transfer themselves from 
one bacterial cell to another. It has been found 
more recently that some resistance genes can jump 
from one plasmid to another, a process known as 
"transposition".
Plasmid mediated resistance has been found to 
both sulphonamides and trimethoprim. Two 
mechanisms for sulphonamide resistance occur. 
Firstly, the production of a new DHPS insensitive 
to sulphonamide, and secondly an impermeability 
mechanism.
Only one major mechanism for trimethoprim 
resistance has been shown, and this involves the 
production of a highly insensitive DHFR. This 
enzyme is, unfortunately, highly specific for 
DHF, and will not bind trimethoprim or metho­
trexate (which resembles folic acid very closely). 
The prospects of designing a new inhibitor to 
block the enzyme are therefore remote.
In-vitro studies on co-trimoxazole 
Recently the original claims for co-trimoxazole 
have been reassessed by a number of workers, 
and I am very grateful to Dr. S. Amyes 
(Department of Microbiology, University of 
Edinburgh) for allowing me to quote his recent 
work on this subject.
Fig. 2 shows a culture of Escherichia coli 
grown in a minimal medium, that is a medium 
containing glucose and some inorganic salts. 
Trimethoprim and sulphonamide are bacteriostatic 
and the growth of the culture is prevented. The 
original claim forecast that their combination 
should be bactericidal, but under these conditions 
the combination is only bacteriostatic. This tends 
to refute the second claim.
Time in Hours
Fig. 2: Effect of trimethoprim and sulphame- 
thoxazole on the viability of E. coli 
in DM. An exponential culture was 
diluted into pre-warmed medium con­
taining no additions ■ : trimethoprim 
(5 mgl-1) A  ; sulphamethoxazole 
(100 mgl-1) □ ; trimethoprim (5mgl-1) 
and sulphamethoxazole (100 mgl-1) 0.
Co-trimoxazole is widely used to treat respir­
atory and urinary tract infections. Conditions in 
the respiratory tract are difficult to model in vitro 
but specimens of urine are much easier to obtain 
and to analyse. Amyes and Smith (1974)5 were 
able to show that conditions in the urine could be 
duplicated quite closely by a minimal medium 
with supplements of some amino acids. The 
addition of methionine, glycine and serine 
produces conditions that duplicate urine as far as 
trimethoprim and sulphamethoxazole action is 
concerned.
When the previous experiment is repeated 
using this medium it can be shown that 0.04 
g/ml trimethoprim has no effect on growth on 
its own, while 0.1 µ g/ml is bacteriostatic (Fig. 
3a) Above 0.1 µ g/ml, however, trimethoprim 
becomes markedly bactericidal when used on 
its own. The concentration of trimethoprim 
achieved in the urine varies between 100-200
µ g/ml. Sulphamethoxazole (Fig. 3b) never 
becomes bactericidal even at concentrations of 
100 µ g/mI.
In summary, therefore, under conditions simi­
lar to those found in the urine co-trimoxazole is 
bactericidal whereas sulphonamide is only bacter­
iostatic. At concentrations greater than 0.1 µ g/ml 
trimethoprim becomes markedly bactericidal by 
itself. The second claim put forward for the 
combination is, therefore, not supported by this 
experiment.
Does synergy occur under conditions similar
to those found in the urine? Fig. 4 shows the 
effect of trimethoprim and sulphamethoxazole 
combined in various ratios. 0.04 µ g/ml trimetho­
prim on its own has no antibacterial action, but as 
the concentration of sulphonamide is increased the 
combination becomes increasingly active, reaching 
its maximum effect at a trimethoprim: sulphame­
thoxazole ratio of 1:20 that is 0.04 µ g/ml of 
trimethoprim to 0.8 µ g/ml sulphamethoxazole. 
Synergy, therefore, can occur under conditions 
similar to those found in the urinary tract. Un­
fortunately the concentration of trimethoprim
Time in Hours
Fig. 3 a & b: Effect of trimethoprim and sulph­
amethoxazole on the viability of E. coli 
in DM supplemented with methio­
nine, glycine and adenine (50 mgl-1 
each). An exponential culture was 
diluted into pre-warmed medium con­
taining the following anti-microbial
drugs. In (a) trimethoprim was used at 
0 ■ : 0.02 mgl-1 0 , 0.04 mgl-1 A  ■ 
0.1 mgl-1 □ ;  0.2mgl-1 • ;  0.4 mgl-1 A;
In (b)| sulphamethoxazole was used at 
0 • ;  0.4 mgl-1 A  ; 0.8 mgl-1 0 ; 
2.0 mgl-1 □  ; 100 mgl-1 A  .
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achieved in the urine is not 0.04 µ g/ml but 100 
at which it is markedly bactericidal on its 
own. Moreover, the trimethoprim: sulpham- 
ethoxazole ration is not 1:20 but 1:2 and there is 
no useful synergistic effect. Synergy would not 
appear, therefore, to be of any practical value 
in the urinary tract. Similar arguments apply to 
the respiratory tract. Indeed there are only two 
areas in the body where the drugs are present 
at the correct ratio for synergy, and they are the 
aqueous humour of the eye and synovial fluid. 
Synergy is unlikely to be of value except in these 
rather specialised areas.
Time in Hours
Fig. 4: Effect of trimethoprim and various 
concentrations of sulphamethoxazole 
on the viability of E  coli K12 in supple­
mented DM. An exponential culture was 
diluted into pre-warmed medium con­
taining trimethoprim at 0.04 mgl-1 and 
sulphamethoxazole at 0 +, 0.04 mgl-1 A 
0.08 mgl-1 A  ;0 .2mgl-1 □  ; 0.4 mgl-1 
O; 0.8 mgl-1 • ;  4.0 mgl-1 ■  .
So far I have considered the action of the 
drugs on sensitive organisms. Figs. 5a and b 
show two strains carrying plasmids that confer 
resistance to sulphonamides. Plasmid SSu confers
an impermeability type mechanism and no synergy 
occurs because the sulphonamiide cannot enter the 
cell. R1 codes for an insensitive DHPS, and yet 
synergy occurs with trimethoprim. This suggests 
that sulphonamide may also bind to the DHFR 
and in this way potentiates the action of trime­
thoprim. It is of no practical value, however, 
because the cell is sensitive to trimethoprim and 
would therefore be destroyed whether the sulpho­
namide was present or not.
Figs. 6a and b show two strains carrying 
plasmids that confer resistance to trimethoprim. 
R483 confers high level trimethoprim resistance, 
that is to concentrations >  1000 µg/ml. The 
addition of sulphonamide produces no 
demonstrable synergy.
R751 also confers high level l 000 µg/ml) 
resistance to trimethoprim, but in this case the 
addition of sulphonamide produces a striking 
enhancement of trimethoprim activity. The com­
bination is markedly bactericidal and far better 
than either drug on its own. This is a remarkable 
result and represents an area where synergy 
would clearly be of advantage.
How do R483 and R751 differ? Studies on 
the enzymes produced by each plasmid show them 
to be similar, possibly even the same enzyme, 
when compared using simple biochemical criteria. 
The major difference appears to be the quantity of 
enzyme produced by each plasmid. A cell 
containing R483 produces more enzyme than 
R751, although quite how this renders it less 
susceptible to synergy is d ifficult to see.
Unfortunately this is of little clinical relevance 
because the majority of plasmid mediated 
resistance genes found in clinical isolates are of the 
R483 type and are therefore totally resistant to 
trimethoprim, irrespective of whether the sulpho­
namide is present or not. R751 resistance is very 
rare having been found once in London, and 
possibly once in Edinburgh. It is therefore of little 
concern clinically.
The claim that synergy occurs and is of value 
in the clinical situation is not supported by these 
experiments. Other in vitro studies have also 
pointed to the dominant role of trimethoprim.
Clinical findings on co-trimoxazole
The third claim made for co-trimoxazole was that 




T im e in Hours
a & b: Effect o f trimethoprim and sul- 
phamethoxazole together on the via­
b ility  of E. coli K12 containing the 
sulphamethoxazole-resistant R-plasmids 
(a) R1 and (b) SSu. Exponential cul­
tures were diluted into pre-warmed
medium containing trimethoprim at 
0.04 mgl-1 ■  or sulphamethoxazole at 
100 mgl-1 □ ; and trimethoprim a t  0.04 
mgl-1 plus sulphamethoxazole at
0.8 mgl-1
100 mgl-1
0 ; 1.6 mgl-1 
A
-1 A  ; 3.2 mgl- 1
T im e in H ours
a & b: Effect of trimethoprim sulphame­
thoxazole together on the viability of 
E. coli K12 containing the trimetho- 
prim-resistance plasmids (a) R751 and 
(b) R483. Exponential cultures were 
diluted into pre-warmed medium con­
taining trimethoprim at 5 mgl-1 ■  or 
50 mgl-1 0 ;  sulphamethoxazole at 
100 mgl-1 A  or 1000 mgl-1 □  ; 
trimethoprim/sulphamethoxazole 
together at 5 mgl-1/100 mgl-1 •  or 
50 mgl-1/1000 mgl-1 A  .
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resistant bacteria. Sulphonamide resistance was 
common amongst bacteria even in 1968 when co- 
trimoxazole was introduced. It is difficult to put 
a precise figure on any resistance level because 
there is tremendous variation between surveys 
carried out in different areas. This probably 
reflects differences in the samples chosen for 
study; e.g. inpatients vs outpatients, the range of 
organisms encountered, local antibiotic usage 
patterns, and possibly laboratory test methods. 
Many studies suggest, however, that sulphonamide 
resistance is present in over 50%  of all clinical 
bacteria, so many must have already been exposed 
to trimethoprim alone.
Resistance to trimethoprim was found very
soon after its introduction, R-plasmids being 
isolated within one year of co-trimoxazole coming 
on to the market: few people suspected that 
R-plasmids would emerge this quickly.
It is difficult to estimate the current level of 
trimethoprim resistance. Work by Grüneberg 
(1980)6 suggests that resistance amongst urinary 
tract pathogens has not increased dramatically 
since its introduction. Undoubtedly, more hospital 
acquired infections are resistant. Table 1 reviews 
a number of reports from European centres. 
French workers reported a high incidence of 
resistance (17%), whilst the incidence rose in Italy 
from 13% to 30%  over a three-year period. Other 
continental reports show similar levels.
T A B LE  1
Percentage of organisms with minimum inhibitory concentration of greater than 10 mgl-1 trime­
thoprim and those possessing trimethoprim R-plasmids (shown in parentheses).
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Reports from the United Kingdom intially 
showed low levels of 2.5% and 4.3% but this 
increased from 8 %  to 10% in London over the 
period 1977-1978. Taken as a whole these figures 
suggest a gradual increase in resistance, which 
makes the figures from Nottingham (which show a 
decline), rather surprising. Closer examination 
shows that there was a small epidemic of resistant 
Kelbsiella spp. in 1978, which probably biases 
the result, but the level of resistance must still 
be relatively low. A  recent study carried out in a 
number of Edinburgh hospitals suggests a much 
higher level of resistance (26%) than has been 
found before.
Turku is an area in Finland where trime­
thoprim has been used extensively on its own. A  
figure of 20%  resistance amongst isolates is high, 
but is certainly in keeping with other areas where 
only the combination has been used, such as 
Edinburgh. The results of these surveys, although 
limited, suggest that resistance in an area where 
trimethoprim has been used alone is probably no 
higher than in many places where only cotrim- 
oxazole has been used. A  number of reports have 
found lower resistance levels. This may reflect 
sampling isolates from general practice or from 
hospitals serving different populations, or from 
areas where the use of co-trimoxazole has been
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more limited.
If the percentage of resistance that is plasmid- 
mediated is examined, then a trend is revealed. 
Undoubtedly the percentage of plasmid-mediated 
trimethoprim resistance is increasing (even in 
Nottingham), and the range of plasmids is 
probably diversifying as the trimethoprim 
resistance genes transpose on to new plasmids.
In summary, therefore, resistance to trime­
thoprim varies from centre to centre. It is always 
higher in hospitals and in areas where trime­
thoprim has been used extensively, irrespective of 
whether it is combined with a sulphonamide or 
not. Plasmids carrying trimethoprim resistance 
are becoming increasingly common, and those 
carrying resistance to sulphonamides have been 
widespread for many years. I see no suggestion 
that the sulphonamide has in any way prevented 
the emergence of trimethoprim resistance and this 
would suggest that the third claim made for the 
combination is not vaild.
There are some similarities between trime­
thoprim resistance and ampicillin resistance. 
Ampicillin was released in 1960 and plasmids 
were found within one year. Initially most 
resistance was chromosomal but gradually the 
percentage due to R-plasmids increased (Richards 
and Datta 1981 )7 and the plasmid pool diversified 
as the T E M -B-lactamose transposed on to new 
plasmids. In the early 1970's, ampicillin resistance 
spread to Haemophilus influenzae and then 
to Neisseria gonorrhoeae. It worries me that 
trimethoprim resistance is also capable of trans­
position and I wonder if R-plasmid trimethoprim 
resistant Haemophilus spp. may emerge one day.
Conclusions
A  hypothetical story relates that a group of 
aeronautical engineers once analysed the aero­
dynamic properties of the bumble-bee and 
"proved" that it couldn't fly. Co-trimoxazole to 
the bee; it doesn't work on paper but is "flies" 
in practice, and therefore why abandon a drug 
that obviously works well in the clinical setting?
I would suggest that the undoubted success of 
co-trimoxazole is due to trimethoprim, and to 
trimethoprim alone. Various clinical studies have 
shown no significant difference between co- 
trimoxazole and trimethoprim. Only one study, 
by Gleckman (1973) 8 has ever shown any
significant advantage for the combination in the 
clinical situation. In this study over one third 
of the organisms cultured were from species of 
Klebsiella, Enterobacter and Proteus, which can 
be very variable in their resistances. No attempt 
was made to find the source of the bacteriuria, 
which could therefore reflect anything from 
pyelonephritis to a simple bladder infection. 
Courses of treatment were carried on for up to 
55 days. Finally, although the level of sulpho­
namide resistance was assessed, no assessment of 
trimethoprim resistance was carried out. I do 
not think that this trial can be accepted in view of 
this omission.
There may be disadvantages to using co- 
trimoxazole. Sulphonamides are notorious for 
their side-effects, including Stevens-Johnson 
syndrome which is a severe form of erythema 
multiforme. It is rare but carries a high mortality. 
Wellcome have suggested that adverse reactions 
to co-trimoxazole are seldom severe: rashes 
occur in about 1.6-8% of patients and gastro­
intestinal reactions such as nausea and vomiting 
are usually mild. Up to June 1976 five cases of 
fatal agranulocytosis due to Septrin had been 
reported to the Committee for the Safety of 
Medicines, which represents about one fatality 
in every 50 million treatment courses. Under­
reporting of side-effects, particularly if mild, has 
always been a problem. For example, a 
surveillance study in the West Midlands was able 
to find 19 serious rashes, including three Stevens- 
Johnsons, one of which was fatal and one neutro- 
poenia/thrombocytopoenia which was fatal. Co- 
trimoxazole is now the second most common 
cause of drug-induced thrombocytopoenia in the 
United Kingdom, seven cases being reported in the 
West Midlands, and four cases of agranulocytosis — 
one of which was fatal. Two further cases were not 
reported. This regional survey confirms that the 
national figures underestimate the incidence of 
major complications.
A  clinical trial by Brumfitt and Pursell 
(1972) 9 found co-trimoxazole and trimethoprim 
to be comparable in antibacterial effect, but side- 
effects occurred in 21%  of the co-trimoxazole 
group against only 8 %  in the trimethoprim group. 
When compared with ampicillin and cephalexin, 
trimethoprim was more effective and had less 
than half the incidence of side-effects.
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In conclusion, therefore, there is little 
evidence that the three original claims made for 
co-trimoxazole can be substantiated. The presence 
of the sulphonamide probably contributes little to 
the anti-bacterial action of trimethoprim, certainly 
in the urinary tract, and can cause side-effects. 
It would be premature to comment on respiratory 
tract infections, but it would appear that neither 
the concentrations of the drugs or their con­
centration ratios are in the range where synergy 
would be likely to occur.
The future of trimethoprim is, therefore, 
bright in the short term, but resistance is an 
increasing problem, and plasmid mediated 
resistance in particular may prove troublesome 
in the longer term.
Trimethoprim is a cheap and effective 
antibacterial drug and should be used alone.
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